CGMP/OTC Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Umendra Life Sciences Private Limited, 2026-06-02
Letter issued · posted to fda.gov .
Subject as published: CGMP/OTC Finished Pharmaceuticals/Adulterated
TL;DR
FDA issued a Warning Letter to Umendra Life Sciences Private Limited on 2026-06-02 citing: CGMP/OTC Finished Pharmaceuticals/Adulterated. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umendra-life-sciences-private-limited-721752-06022026
Argus analysis
Umendra Life Sciences Private Limited (MARCS-CMS 721752, FEI 3035187076) received an FDA Warning Letter dated June 2, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: CGMP/OTC Finished Pharmaceuticals/Adulterated. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on June 9, 2026.
Nonprescription/OTC letters typically cite the relevant OTC monograph under 21 CFR Part 330 (or the newer OTC monograph order process under the CARES Act) alongside 21 USC 352 misbranding provisions. Common findings involve active ingredients, dosing, or labeling claims that fall outside the applicable monograph's permitted conditions.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same CGMP (Current Good Manufacturing Practice) category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Umendra Life Sciences Private Limited MARCS-CMS 721752 — June 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS Reference #: 320-26-91 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Ankur Sharma Sr. Recipient Title General Manager – Quality Umendra Life Sciences Private Limited New Survey No. 211, Village Account No. 170 Old Block Survey No. 158, Bavla, Taulka Mauje Ahmedabad 382220 Gujarat India Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-91 June 2, 2026 Dear Mr. Sharma: Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 14, 2025 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Umendra Life Sciences Private Limited, FEI 3035187076, at New Survey No. 211, Village Account No. 170 Old Block / Survey No. 158, Bavla, Taulka Mauje, Amipura, Ahmedabad, Gujarat. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)). Following review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following: 1. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products are manufactured in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22). Your firm manufactures OTC (b)(4) drug products labeled to contain the active ingredient (b)(4) . This drug product is also labeled and formulated to contain the inactive ingredient talc. For one of the drug products, the formulation is composed of more than (b)(4) % talc. Both talc and asbestos are naturally occurring minerals that may be found in close proximity in the earth. Asbestos is a potential contaminant in talc and is a known human carcinogen when inhaled. 1,2 Additionally, published scientific literature dating back to the 1960s has suggested a possible association between the use of (b)(4) containing talc in the (b)(4) area and the incidence of (b)(4) , potentially linked to asbestos contamination of the talc. 3 The (b)(4) you produce can be used on areas of the body which may be an exposure risk (e.g.…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has Umendra Life Sciences Private Limited had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Umendra Life Sciences Private Limited as of 2026-06-09. Argus ingests new FDA enforcement records daily.
- What FDA violations was Umendra Life Sciences Private Limited cited for?
- The FDA Warning Letter to Umendra Life Sciences Private Limited (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/OTC Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Umendra Life Sciences Private Limited?
- FDA issued the letter (MARCS-CMS 721752) on 2026-06-02 and posted it publicly on fda.gov on 2026-06-09.
- Is the FDA warning letter to Umendra Life Sciences Private Limited publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umendra-life-sciences-private-limited-721752-06022026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). CGMP/OTC Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Umendra Life Sciences Private Limited, 2026-06-02. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-umendra-life-sciences-private-limited-2026-06-02-cgmp
"CGMP/OTC Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Umendra Life Sciences Private Limited, 2026-06-02." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-umendra-life-sciences-private-limited-2026-06-02-cgmp.
Argus HQ Research. "CGMP/OTC Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Umendra Life Sciences Private Limited, 2026-06-02." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-umendra-life-sciences-private-limited-2026-06-02-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_umendra_life_sciences_private_limited_2026_06_02_cgmp_2026,
title = {CGMP/OTC Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Umendra Life Sciences Private Limited, 2026-06-02},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-umendra-life-sciences-private-limited-2026-06-02-cgmp},
note = {Accessed: July 13, 2026}
}